1. Home
  2. POM vs BOLT Comparison

POM vs BOLT Comparison

Compare POM & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo POMDOCTOR LIMITED American Depositary Shares

POM

POMDOCTOR LIMITED American Depositary Shares

HOLD

Current Price

$0.71

Market Cap

6.5M

ML Signal

HOLD

Logo Bolt Biotherapeutics Inc.

BOLT

Bolt Biotherapeutics Inc.

HOLD

Current Price

$3.98

Market Cap

7.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
POM
BOLT
Founded
2015
2015
Country
China
United States
Employees
N/A
N/A
Industry
Other Specialty Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
7.1M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
POM
BOLT
Price
$0.71
$3.98
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$34.00
AVG Volume (30 Days)
14.9K
21.2K
Earning Date
05-11-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$7,695,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$133.33
P/E Ratio
N/A
N/A
Revenue Growth
N/A
0.07
52 Week Low
$0.06
$3.13
52 Week High
$6.43
$7.20

Technical Indicators

Market Signals
Indicator
POM
BOLT
Relative Strength Index (RSI) 38.81 54.00
Support Level $0.23 $3.87
Resistance Level $1.17 $4.33
Average True Range (ATR) 0.09 0.28
MACD -0.03 0.02
Stochastic Oscillator 26.99 68.63

Price Performance

Historical Comparison
POM
BOLT

About POM POMDOCTOR LIMITED American Depositary Shares

Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of its revenue is derived from the Pharmaceutical supply chain segment.

About BOLT Bolt Biotherapeutics Inc.

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Share on Social Networks: